发明名称 |
IDENTIFYING PATIENT RESPONSE TO S1P RECEPTOR MODULATOR ADMINISTRATION |
摘要 |
The invention provides a method of assessing the appropriate therapeutic dose of 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid to administer to a patient in need thereof. It is determined whether a patient has a particular metabolizer genotype. If the patient does not have a particular genotype, 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof is administered at a standard dose. If the patient has the poor metaboliser genotype, either 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, is administered at a dose below that of the standard therapeutic dose; or is not dosed at all. |
申请公布号 |
SG11201506493V(A) |
申请公布日期 |
2015.10.29 |
申请号 |
SG11201506493V |
申请日期 |
2013.04.19 |
申请人 |
NOVARTIS AG |
发明人 |
BORELL, HUBERT;GARDIN, ANNE;JIN, YI;LEGANGNEUX, ERIC;UFER, MIKE |
分类号 |
C12Q1/68;G01N33/50;G01N33/569 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|